F/R@30=9

F/R@30=9.00 vs. and GTP, which is usually critically required for recognition of translation start codon. Hydrolysis of GTP in the eIF2GTPMet-tRNAiternary complex and release of inorganic phosphate, Pi, are coupled to start-codon recognition and initiation of translation. The exchange of GDP in the eIF2GDP binary complex for GTP is usually catalyzed by eIF2B, a guanine nucleotide exchange factor. This GDP-GTP exchange is the rate-limiting step for the formation of the ternary complex and initiation of a new round of translation. Phosphorylation of alpha subunit of eIF2 (eIF2) on S51 by eIF2 kinases- HRI, RNA-dependent-protein-kinase/protein kinase R (PKR), pancreatic eIF2 kinase/PKR-like endoplasmic reticulum kinase (PERK), and general control non-derepressible-2 (GCN2)- is the major mechanism that regulates the GDP-GTP exchange. More specifically, S51 phosphorylation on eIF2 concomitantly increases its affinity for eIF2B and inhibits eIF2Bs guanine nucleotide exchange activity. Because the eIF2 is present in excess over eIF2B (low eIF2B/eIF2 stoichiometry), even partial phosphorylation of eIF2 results in sequestration of eIF2B thereby reducing the amount of the eIF2GTPMet-tRNAiternary complex, and inhibiting translation initiation1,2. Formation of the eIF2GTPMet-tRNAiternary complex is tightly coupled to cell physiology and plays critical roles in normal- and patho-biology39. Proliferating cells synthesize proteins at much higher rate than quiescent cells of comparable types. The lower rate of translation in quiescent cells is usually achieved in part by higher rate of eIF2 phosphorylation compared to proliferating cells. Phosphorylation of eIF2 is essential for coupling protein synthesis to heme availability in red blood cells progenitors, to the folding capacity of ER-Golgi network in the secretory cells, and to the nutrient and oxygen availability in almost all cells. Consistent with its role in the normal-biology, deregulation of eIF2 phosphorylation is usually implicated in the patho-biology of various human disorders. For example, inactivating mutations of PERK cause Wolcott-Rallison syndrome, a rare autosomal recessive disease characterized by neonatal/early-onset non-autoimmune insulin-requiring diabetes associated with skeletal dysplasia and growth retardation syndrome10,11. Insufficiency of eIF2 phosphorylation in red blood cells progenitors, i.e. those deficient in HRI, increases the severity of hemolytic disorders such as -thalassemia1214. Deregulation of eIF2 phosphorylation has also been implicated in the pathogenesis of neurodegenerative disorders such as Alzheimers disease and proliferative disorders such as cancer15,16. Forced expression of eIF2-S51A, a non-phosphorylatable mutant, increases the amount of the ternary complex, renders the translation initiation unrestricted, and causes transformation of normal cells17,18. Similarly, overexpression of MettRNAi, which increases the amount of the ternary complex, causes cellular transformation19. In contrast, induction of eIF2 phosphorylation pharmacologically or by over-expressing eIF2 kinases inhibits proliferation of cancer cellsin vitroand tumor growthin Hdac11 vivo2024. These findings clearly indicate that small molecule activators of eIF2 kinases, particularly of HRI, are important tools for studying the patho-biology of certain human disorders and/or may be deployed for their treatment. This task is usually highly dependent on discovery of HRI activators whose potency, specificity, and physico-chemical properties can be improved by structure-activity relationship (SAR) studies. Such hits should ideally be based on druggable molecular scaffolds suitable for facile synthesis. We previously reported discovery and preliminary SAR studies ofN,N-diarylureas as activators of HRI25,26.N,N-diaryl- as well asN-aryl,N-alkyl-ureas, such as 12-(3-adamantane-1- ylureido)dodecanoic acid (AUDA), were reported to be potent inhibitors of soluble epoxide hydrolase (sEH)27,28. We therefore advanced the hypothesis thatN,N-disubstituted urea analogs other thanN,N-diarylureas may also activate HRI and AZD3229 Tosylate induce eIF2 phosphorylation. If correct, this will allow greater structural versatility that will lend itself to the discovery and development of more potent and selective HRI activators. Herein, we report screening of a ~1,900 member diversityN,N-disubstituted urea library, originally developed to inhibit sEH29,30and discovery AZD3229 Tosylate ofN-phenyl,N-cyclohexylphenoxy compounds as activators of HRI. We evaluated selected hit compounds for induction of endogenous eIF2 phosphorylation and expression of its downstream effector, CHOP protein and mRNA, and inhibition of the expression of oncogenic proteins. We further decided the dependence of the activity of these brokers on HRI at the molecular and cellular level. We then undertook structure-activity relationship study of novel HRI activators as the first step in a hit-to-lead optimization process. AZD3229 Tosylate To this end, we synthesized focused libraries ofN-phenyl,N-cyclohexylphenoxy ureas to assess structural latitude and improve their potency. These AZD3229 Tosylate newly synthesized compounds were characterized for induction of eIF2 phosphorylation in a surrogate cell-based reporter assay as well as inhibition of cell proliferation in sulforhodamine B (SRB) binding assay, which assessed the biological.